News
Press releases and company updates.
- GTA182Apeiron Therapeutics Presents First-in-Human Data from Phase 1 Clinical Trial of GTA182 in MTAP-Deleted Advanced Non-Small Cell Lung Cancer at the ESMO Asia Congress 2025
- GTA182Apeiron Therapeutics to Present FiH Phase 1 Data on PRMT5 Inhibitor GTA182 at ESMO Asia 2025
- GTA182Apeiron Therapeutics Presents Preclinical Data from its Oncology Program on PRMT5 Inhibitor GTA182 at AACR 2025 Annual Meeting
- GTA182Apeiron Therapeutics to Present Preclinical Data on PRMT5 Inhibitor GTA182 at AACR 2025 Annual Meeting
- GTA182Apeiron Enrolls First Patient in Phase 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors
- GTA182Apeiron Receives IND Clearance from NMPA for next generation PRMT5 Inhibitor GTA182 to Treat MTAP Null Tumors
- CorporateApeiron to Expand Investment in Synthetic Lethality Pipeline After New Phase in Collaboration with Exscientia
- GTA182GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers
- CDK7GT Apeiron Announces Enrollment of First Patient in Phase 1/2 “ELUCIDATE” Clinical Trial of CDK7 Inhibitor, GTAEXS617, in Advanced Solid Tumors
- KIF18AApeiron will present the latest research on KIF18A at AACR 2023
- CDK7Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
- CorporateApeiron Closes $17.5 Million Series A and Launches Strategic Partnerships
- CDK7Apeiron is making its debut at AACR
- CorporateExscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture
- CorporateGT Apeiron Therapeutics Strengthens Advisory Board
- CorporateApeiron Therapeutics opens US headquarter
- CorporateApeiron founded and announces its partnership with Exscientia
Media and investor inquiries: inquiries@apeiron-bio.us